Information de reference pour ce titreAccession Number: | 00000013-200110000-00002.
|
Author: | Breivik, H.
|
Institution: | Department of Anaesthesiology, Rikshospitalet, University of Oslo, Norway
|
Title: | Opioids in cancer and chronic non-cancer pain therapy - indications and controversies.[Review]
|
Source: | Acta Anaesthesiologica Scandinavica. 45(9):1059-1066, October 2001.
|
Abstract: | Indications for strong opioids for cancer-related pain as well as for chronic non-cancer pain are that non-opioid drugs, and other less risky therapies, fail and that the pain is opioid-sensitive. The WHO analgesic ladder principle continues to serve as an excellent educational tool in the efforts by WHO in collaboration with the World Federation of Societies of Anaesthesiologists (WFSA) and The International Association for the Study of Pain (IASP) to increase knowledge of pharmacological pain therapy and increase availability of essential opioid analgesics world-wide. Opioids differ in pharmacodynamics and pharmacokinetics, and patients have different pharmacogenetics and pain mechanisms. Sequential trials of the increasing numbers of available opioid drugs are therefore appropriate when oral morphine fails.
Controversies continue concerning diagnosis and handling of opioid-insensitive pain in cancer and chronic non-cancer pain, opioid-induced neurotoxicities, risks of tolerance, addiction, pseudo-addiction, and methods for improving effectiveness and decreasing adverse effects of long-term opioid therapy, treating breakthrough pain with immediate release oral and transmucosal opioids.
Consensus guidelines have recently been developed in the Nordic countries concerning the ethical practice of palliative sedation when opioids and other pain-relieving therapies fail in patients soon to die. Guidelines for long-term treatment with strong opioids of chronic non-cancer-related pain are also being developed in the Nordic countries, where very diverging traditions for the usage of such therapy still exist.
(C) 2001 The Acta Anaesthesiologica Foundation.
|
Author Keywords: | Opioid analgesics; cancer pain; chronic non-cancer pain; opioid induced neurotoxicities; morphine; oxycodone; hydromorphone; fentanyl, transdermal; transmucosal; palliative sedation; addiction; pseudoaddiction.
|
References: | 1. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999: 353: 1695-1700.
2. Hanks GW, de Conno F, Hanna M, Kalso E, McQuay HJ, Mercadante S et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001: 84: 587-593.
3. WHO. Cancer pain relief. With a guide to opioid availability. 2nd edn, Geneva: World Health Organisation, 1996.
4. Breivik H. Nerve blocks - simple injections, epidurals, spinals, and more complex blocks. In: Simpson KH, Budd K, eds. Cancer pain management: a comprehensive approach. Oxford: Oxford University Press, 2000: 84-98.
5. Warncke T, Breivik H, Vainio A. Treatment of cancer pain in Norway. Pain 1994: 57: 109-116.
6. U.S. Dept. of Health and Human Services. Management of cancer pain. Rockville, MD: AHCPR Publication 94-0693, 1994.
7. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993: 341: 1075-1076.
8. Arner S, Arner B. Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand 1985: 29: 32-36.
9. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988: 33: 11-23.
10. Sjogren P, Jonsson T, Jensen H-N. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993: 55: 93-97.
11. Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 1999: 43: 918-923.
12. Mayer DJ, Mao J. Mechanisms of opioid tolerance. A current view of cellular mechanisms. Pain Forum 1999: 8: 14-18.
13. Bohn LM, Gainetdinow RR, Lin F-T, Lefkowitz RJ, Caron MG. [mu]-opioid receptor desensitization by [beta]-arrestin-2 determines morphine tolerance but not dependence. Nature 2000: 408: 720-723.
14. Meunier J-C. Nociceptin as an antiopioid: Where do we stand? European Federation of IASP-Chapters: Pain in Europe III, Nice, Sept. 26-29, 2000, Abstract OTS/02/2.
15. Crain SM, Shent K-F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000: 84: 121-131.
16. Mercadante S. Methadone in cancer pain. Eur J Pain 1997: 1: 77-85.
17. Breivik H. Methadone in cancer pain. Eur J Pain 1997: 1: 86-87.
18. Zenz M. Methadone in cancer pain. Eur J Pain 1997: 1: 235-236.
19. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000: 356: 2069-2070.
20. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990: 47: 639-646.
21. Ross FB, Wallis SC, Smith MT. Co-administration of subantinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side effects in rats. Pain 2000: 84: 421-428.
22. Kalso E. Route of opioid administration: Does it make a difference? In: Kalso E, McQuay HJ, Wiesenfeldt-Hallin Z, eds. Opioid sensitivity of chronic non cancer pain. Progress in Pain Research and Management 1999: 14: 117-128.
23. Niemi G, Breivik H. Adrenaline markedly improves thoracic epidural analgesia produced by a low-dose infusion of bupivacaine, fentanyl and adrenaline after major surgery. A randomised, double-blind, cross-over study with and without adrenaline. Acta Anaesthesiol Scand 1998: 42: 897-909.
24. Tammisto T, Tammisto Ch. Injection of morphine loco dolenti recommended as early as 1876. Acta Anaesthesiol Scand 2000: 44: 520-523.
25. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999: 353: 1959-1964.
26. Portenoy RK, Paine R, Coluzzi P et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999: 79: 303-312.
27. Weber W. Dutch euthanasia law passed by parliament. Lancet 2000: 356: 1911.
28. Hardy J. Sedation in terminally ill patients. Lancet 2000: 356: 1866-1867.
29. Forde R, Aasland OG, Falkum E, Breivik H, Kaasa S. Lindrende sedering til doende i Norge (Palliative sedation to the dying patient). Tidsskr Nor Laegeforen 2001: 121: 1085-1088.
30. Forde R, Breivik H, Falkum E, Halvorsen E, Husabo EJ, Kaasa S. Retningslinjer for lindrende sedering til doende. (Guide-lines for palliative sedation to the dying patient). Oslo: Den Norske Laegeforening, 2001.
31. Becker N, Sjogren P, Bech P, Olsen AK, Eriksen J. Treatment outcome of chronic non-malignant pain patients managed in a Danish multidisiplinary pain center compared to general practice: a randomised controlled trial. Pain 2000: 84: 203-211.
32. Weissman DE, Haddox JD. Opioid pseudo-addiction - an iatrogenic syndrome. Pain 1989: 36: 363-366.
33. Savage SR. Opioid therapy of chronic pain: Assessment of consequences. Acta Anaesthesiol Scand 1999: 43: 909-917.
34. Dunbar SA, Katz NP. Chronic opioid therapy for non-malignant pain in patients with a history of substance abuse: Report of 20 cases. J Pain Symptom Manage 1996: 11: 163-171.
35. Dellimijn P, van Duijn H, Vanneste J. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998: 16: 220-229.
36. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Minggao SHI et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomised, multicenter, placebo controlled trial. J Rheumatol 1999: 26: 862-869.
37. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology 1998: 50: 1837-1841.
38. Moulin DE, Iezzi A, Amireh R, Sharpe WKJ, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996: 347: 143-147.
39. Long SP. Pain subcommittee presents opioid and chronic pain guidelines to Medical Society of Virginia House of Delegates at Annual Meeting. Am Soc Reg Anesth News 1998: 5: 6-9.
40. Schug SA, Large RG. Opioids for chronic noncancer pain. Pain: Clinical Updates. Seattle: Internat Ass Study Pain Press 1995: 3: 1-4.
41. Federation of State Medical Boards of the United States. Model guidelines for the use of controlled substances for the treatment of pain. Euless: Federation of State Medical Boards of the United States, Inc., 1998.
42. Breivik H. Sterke opiatanalgetika for kroniske smerter (Strong opiate analgesics for chronic pain). Tidsskr Nor Laegeforen 1983: 103: 1491-1493.
43. Portenoy RK. Opioid therapy for chronic nonmalignant pain: current status. In: Fields HL, Liebeskind JC, eds. Pharmacological approaches to the treatment of chronic pain: New concepts and critical issues. Progress in Pain Research and Management. IASP Press, 1994: 1: 247-287.
44. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997: 13: 6-8.
45. Gramstad L, Haugtomt H, Breivik H. Use of opioids in chronic non-cancer pain - current status in Norway. In: Kalso E, Paakari P, Stenberg I, eds. Opioids in chronic non-cancer pain. Situation and guidelines in the Nordic Countries. Helsinki: National Agency for Medicines, 1999.
46. Canadian Pain Society. Use of opioid analgesics for the treatment of chronic non-cancer pain - A consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 1998: 3: 197-208.
47. Kalso E, Paakari P, Stenberg I, eds. Opioids in chronic noncancer pain. Situation and guidelines in the Nordic countries. Helsinki: National Agency for Medicines, 1999.
48. Terapianbefaling: Sterke opioide analgetika for kronisk ikke-cancer relatert smerte. (Therapeutic guidelines: Strong opioid analgesics for chronic non-cancer pain). Oslo and Stockholm: Statens Legemiddelverk, Lakemedelverket, 2001.
|
Language: | English.
|
Document Type: | Review Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0001-5172
|
NLM Journal Code: | 0370270
|
Annotation(s) | |
|
|